Browse News
Filter News
Found 301 articles
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
4/2/2024
Avalo Therapeutics, Inc. announced the addition of multiple biotech leaders to its Board of Directors.
-
Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development
4/1/2024
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development.
-
Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria
2/2/2024
Synlogic, Inc. (Nasdaq: SYBX) announced today the publication of a manuscript detailing the development and activity of SYNB1353 in preclinical models and demonstrating safety, tolerability, and clinical proof of mechanism in healthy volunteers through the successful lowering of methionine (Met), a precursor to homocysteine, in a dietary model of classical homocystinuria (HCU).
-
Ginkgo Bioworks Announces Inaugural Members of New Biopharma Advisory Board
1/8/2024
f, which is building the leading platform for cell programming and biosecurity, announced the formation of its new Biopharma Advisory Board.
-
Synlogic Announces Contract with the Air Force Research Lab
12/27/2023
Synlogic, Inc. announced that it has entered into an approximately $1 million subcontract under an Air Force Research Lab prime contract to develop a manufacturing process to support development of a potential live probiotic product.
-
Synlogic Announces Abstract Accepted for Poster Presentation at the International Conference on Microbiome Engineering 2023
12/7/2023
Synlogic, Inc. announced that an abstract outlining the SYNB1353 program as a potential treatment for homocystinuria (HCU) has been accepted and will be presented at the International Conference on Microbiome Engineering 2023, held in Berkeley, California on December 8th to 10th.
-
Mural Oncology Launches to Advance Pipeline of Novel Engineered Cytokine Immunotherapies
11/15/2023
Mural Oncology plc launched as an independent, publicly traded, clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and protein engineering to develop novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers.
-
Synlogic Announces Pricing of $21.0 Million Underwritten Public Offering
9/29/2023
Synlogic, Inc. announced the pricing of an underwritten public offering of 7,394,363 shares of common stock and accompanying common warrants to purchase up to an aggregate of 7,394,363 shares of common stock.
-
Synlogic Announces CEO Aoife Brennan Named to PharmaVoice 100
9/19/2023
Synlogic, Inc. announced that CEO Aoife Brennan, M.B. Ch.B., has been honored as a PharmaVoice 100 winner, a list recognizing the most inspiring people in the life sciences industry.
-
Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business Updates
8/10/2023
Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the quarter ended June 30, 2023, and provided pipeline and business updates.
-
Synlogic Partners with Science 37 on Pivotal Study for Investigational Drug for Phenylketonuria (PKU)
7/11/2023
Science 37 Holdings, Inc. (Nasdaq: SNCE), the clinical research industry-leading Metasite™ has been chosen by Synlogic, (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases in need of new treatment options.
-
Synlogic Granted Fast Track Designation from FDA for labafenogene marselecobac (SYNB1934) for Treatment of Phenylketonuria
7/11/2023
Synlogic, Inc. announced that the U.S. Food and Drug Administration has granted Fast Track designation to labafenogene marselecobac for the treatment of phenylketonuria.
-
Synlogic Announces International Nonproprietary Name Selection for SYNB1934
6/28/2023
Synlogic, Inc. today announced that the International Nonproprietary Names (INN) Expert Committee of the World Health Organization (WHO-INN) has selected "labafenogene marselecobac" for the nonproprietary name of the company’s investigational drug for phenylketonuria (PKU), previously known as SYNB1934.
-
Synlogic Announces Participation in SVB Securities Healthcare Therapeutics Forum
6/27/2023
Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today announced that its management team will participate in the SVB Securities Healthcare Therapeutics Forum, being held in New York, July 11-12, 2023.
-
Synlogic Reminds Stockholders of 2023 Annual General Meeting Details
6/8/2023
Synlogic, Inc., the leading company advancing therapeutics based on synthetic biology, reminded stockholders that it will hold its 2023 Annual General Meeting of Stockholders on Thursday, June 15, 2023 at 8:00 a.m. EST.
-
Synlogic Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of Phenylketonuria
6/5/2023
Synlogic, Inc. announced the initiation of Synpheny-3, a global, pivotal Phase 3 study evaluating the efficacy and safety of SYNB1934 as a potential treatment for phenylketonuria.
-
Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer
5/22/2023
Athira Pharma, Inc. today announced the appointment of Andrew Gengos as Chief Financial Officer and Chief Business Officer, effective immediately.
-
Synlogic Receives Orphan Drug Designation from FDA for SYNB1934 for Treatment of Phenylketonuria
5/9/2023
Synlogic, Inc., the leading company advancing therapeutics based on synthetic biology, announced that the U.S. Food and Drug Administration has granted orphan drug designation to SYNB1934 for the treatment of phenylketonuria.
-
Ginkgo Bioworks Previews Today's Annual Ferment Conference - April 19, 2023
4/19/2023
Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, is hosting its annual conference, Ferment.